JP2023517078A5 - - Google Patents
Info
- Publication number
- JP2023517078A5 JP2023517078A5 JP2022554294A JP2022554294A JP2023517078A5 JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5 JP 2022554294 A JP2022554294 A JP 2022554294A JP 2022554294 A JP2022554294 A JP 2022554294A JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- administered
- subject
- approximately
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988312P | 2020-03-11 | 2020-03-11 | |
| US62/988,312 | 2020-03-11 | ||
| PCT/US2021/021527 WO2021183529A1 (en) | 2020-03-11 | 2021-03-09 | Methods of treating her2 mutant cancers with tucatinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517078A JP2023517078A (ja) | 2023-04-21 |
| JP2023517078A5 true JP2023517078A5 (cg-RX-API-DMAC7.html) | 2024-03-19 |
Family
ID=75278374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554294A Pending JP2023517078A (ja) | 2020-03-11 | 2021-03-09 | ツカチニブを用いてher2突然変異を有するがんを処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230136203A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4118237A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023517078A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220152287A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115698338A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174986A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296227A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011160A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021183529A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3615067A1 (en) | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| KR20220086627A (ko) * | 2019-10-21 | 2022-06-23 | 시아겐 인크. | 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| WO2019241599A1 (en) * | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
-
2021
- 2021-03-09 US US17/910,265 patent/US20230136203A1/en not_active Abandoned
- 2021-03-09 WO PCT/US2021/021527 patent/WO2021183529A1/en not_active Ceased
- 2021-03-09 KR KR1020227034924A patent/KR20220152287A/ko not_active Withdrawn
- 2021-03-09 EP EP21715395.6A patent/EP4118237A1/en active Pending
- 2021-03-09 IL IL296227A patent/IL296227A/en unknown
- 2021-03-09 CA CA3174986A patent/CA3174986A1/en active Pending
- 2021-03-09 JP JP2022554294A patent/JP2023517078A/ja active Pending
- 2021-03-09 MX MX2022011160A patent/MX2022011160A/es unknown
- 2021-03-09 CN CN202180032665.9A patent/CN115698338A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005314461B2 (en) | Methods and compositions for treating ocular disorders | |
| WO2017147594A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| KR20210132045A (ko) | 안지오포이에틴-유사 7(angtl7) 억제제를 사용하는 안구 질환의 트리트먼트 | |
| KR20230041709A (ko) | G-단백질 결합 수용체 75 (gpr75) 억제제를 사용한 비만 치료 | |
| JP2026084693A (ja) | TNFα拮抗薬を使用したドライアイ疾患の治療方法 | |
| US20180263979A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| US20230136203A1 (en) | Methods of treating her2 mutant cancers with tucatinib | |
| WO2007106424A2 (en) | Treating cancers with activated ras through inhibition of pkc delta | |
| US12048699B2 (en) | Cancer treatment methods based on TP53 mutation status and hypermutation | |
| JP2009511057A (ja) | 黄斑変性に関与する遺伝子 | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| CN115244179A (zh) | 用于治疗和预防前激肽释放酶相关疾患的组合物和方法 | |
| US20250075216A1 (en) | Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors | |
| RU2812912C2 (ru) | Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7) | |
| HK1113690B (en) | Methods and compositions for diagnosing age-related macular degeneration | |
| KR20170076480A (ko) | Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도 |